M42 is driving healthcare transformation via cutting-edge technologies, including regenerative medicine and personalized treatments.
In an era where healthcare costs are escalating, one UAE-based company is disrupting the industry. Enter M42, a first-of-its-kind, tech-enabled health powerhouse, formed in April 2023 and dedicated to shaping the sustainable future of health. Leveraging cutting-edge technologies, M42 focuses on empowering individuals by putting health back in their hands. It prioritizes people, not just patients. It enables prevention, not just treatment.
This personalized, preventative approach is more relevant than ever before, as the global healthcare system is at a critical juncture. Healthcare costs are rapidly rising, and the World Health Organization predicts a shortfall of 10 million healthcare professionals by 2030. In the UAE, health expenditure is projected to reach $30 billion by 2027. Transformative change is necessary, and fast.
Transformative technologies
As a health-tech innovator, M42 addresses these challenges by leveraging emerging technologies like AI, genomics and big data. Strategic collaborations, such as its ongoing partnerships with Microsoft, the Broad Institute of MIT and Harvard, and the International Center for Genetic Disease, all help to lay the foundation for precise and preventive healthcare.
Furthermore, M42 leverages AI algorithms in many of its procedures, including early cancer detection and robotic surgeries, enhancing precision while minimizing recovery times and reducing treatment costs. Real-time wearable monitoring, another growth area, supports chronic disease management and elderly care. This in turn enables timely interventions to keep patients healthier, reducing the length and frequency of their hospital stays while easing the pressure on the healthcare system.
The genomic era
M42 leads the region in human genomics, transforming our collective understanding of DNA’s role in health and disease. The company is currently running the Emirati Genome Program, one of the largest population genome projects globally. “Genetic testing can identify up to 90 percent of the most common genetic mutations for certain inherited conditions, allowing for early prevention and precision health solutions. Our integration of AI, genomics and big data across 450 locations, spanning 26 countries, is driving advancements in health and I am excited as to where we are going,” says Ashish Koshy, Group Chief Operating Officer of M42.
Democratizing health
M42’s “Med42”, an open-access AI Clinical Large Language Model (LLM), is another innovation with revolutionary potential, given its unmatched precision and accessibility. It streamlines medical workflows, reducing administrative burdens by up to 50 percent. Reviewed by expert physicians worldwide, it boasts a zero-shot accuracy score of 85.1 percent on the United States Medical Licensing Examination, positioning it as a frontrunner in open-access clinical LLM technology alongside proprietary models such as OpenAI’s GPT-4 and Google’s Med-Gemini.
“It’s estimated that by 2025 there will be 11,000 exabytes of healthcare data, more than any other industry in the world,” says Ashish. “It’s therefore crucial that we have efficient methods of not only analyzing this data but also being able to extract actionable insights from it.”
He added, “Innovation isn’t just a buzzword at M42; it’s in our DNA. Tech isn’t just about algorithms; it’s about democratizing health solutions so that everyone benefits. We’re not just treating patients; we’re preventing health issues before they arise.”
The future of healthcare lies in innovation, collaboration and investment in transformative technologies. By reshaping the sustainable future of health, M42 is inspiring confidence in a brighter, healthier future for all.
Learn more about M42’s initiatives here.
Find out more about Global Health campaign
